



01-08-0 17400 0400 0500
EL897831513US

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this paper and any documents referred to as enclosed or attached are being deposited with the United States Postal Service on this date in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL897831513US addressed to:

Commissioner of Patents
Washington, D.C. 20231
BOX IDS-NON FEE

on 1/4/2002
Date

Bonnie Ferguson
Signature of Person Making Deposit
Bonnie S. Ferguson
Printed Name of Person Making Deposit

Applicant: Devries et al

Title: METHOD AND COMPOSITIONS FOR TREATMENT OF OCULAR
NEOVASCULARIZATION AND NEURAL INJURY
Allergan Docket: 17400 (BAR)

Enclosed Are:

Certification Under 37 CFR 1.10 (Express Mail Label No.
EL897831513US

1. POSTCARD
2. CERTIFICATE OF MAILING BY EXPRESS MAIL
3. INFORMATION DISCLOSURE STATEMENT
4. PTO 1449 AND REFERENCES

7

17400(BAR)



#2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DeVries et al.

Group Art Unit: Not yet assigned

Serial No.: 10/020541

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail (Label No. EL897831513US) in an envelope addressed to: Box IDS-Non-Fee, Commissioner for Patents, Washington, D.C. 20231 on:

Filed: Herewith

Date of Deposit: 1/4/2002

For: Methods and Compositions
for Treatment of Ocular Neo-
Vascularization and Neural Injury

Person making Deposit: BONNIE FERGUSON

Signature: Bonnie Ferguson

Date of Signature: 1/4/2002

Examiner: Not yet assigned

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicant herewith submits forms PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR § 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentability of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Applicant respectfully requests that the Examiner indicate consideration of the presently cited references by returning the enclosed Form 1449 bearing the Examiner's initials and the date considered.

As this Information Disclosure Statement is being submitted prior to three months after the filing date of this Application, no fee or certification is thought to be required, pursuant to 37 CFR §1.97(b). If Applicant is in error in this regard, please use Deposit Account 01-0885 for payment of any fee that may be due.

Respectfully submitted,


Date:

1/4/02



Carlos A. Fisher
Reg. No. 36,510
ALLERGAN, INC.
T2-7H
2525 Dupont Drive
Irvine, CA 92612
Tel: 714-246-4920
Fax: 714-246-4249

LIST OF REFERENCES CITED BY APPLICANT

ATTY. DOCKET: 17400(BAR)		SERIAL NO.: 10/020,541
APPLICANT: DeVries et al		TITLE: METHODS AND COMPOSITIONS FOR TREATMENT OF OCULAR NEOVASCULARIZATION AND NEURAL INJURY
FILING DATE: October 30, 2001		GROUP: Not Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	5,756,541	5/1998	Strong et al			
	AB	5,958,875	9/1999	Longo et al			
	AC	6,100,254	8/2000	Budde et al			
	AD	5,443,505	8/1995	Wong et al			
	AE	5,824,072	10/1998	Wong			
	AF	5,766,242	6/1998	Wong et al			
	AG	4,853,224	8/1989	Wong			
	AH	4,997,652	3/1991	Wong			
	AI	5,164,188	11/1992	Wong			
	AJ	5,632,984	5/1997	Wong et al			
	AK	5,869,079	2/1999	Wong et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	AH						

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, etc.)

	AI	Reinke et al, "Verteporfin Photodynamic Therapy Retreatment of Normal Retina and Choroid in the Cynomolgus Monkey", Ophthalmology 106: 1915-1923 (October 1999)
	AJ	Tombran-Tink et al, "PEDF: A Pigment Epithelium-derived Factor with Potent Neuronal Differentiative Activity", Exp. Eye Res. 53: 411-414 (1991)
	AK	Dawson et al, "Pigment Epithelium-Derived Factor: A Potent Inhibitor of Angiogenesis", Science 285:245-248 (9 July 1999)
	AL	Becerra et al, "Pigment Epithelium-derived Factor Behaves Like a Noninhibitory Serpin", J. Biol. Chem. 270:25992-25999 (1995)
	AM	Lambiase et al, "Nerve growth factor delays retinal degeneration in C3H mice", Graefe's Arch. Clin. Exp. Ophthalmol. 234:S96-S100 (1996)
	AN	Cayouette et al, "Intraocular Gene Transfer of Ciliary Neurotrophic Factor Prevents Death and Increases Responsiveness of Rod Photoreceptors in the retinal degeneration slow mouse", J. Neurosci. 18:9282-9293 (1998)



LIST OF REFERENCES CITED BY APPLICANT

ATTY. DOCKET: 17400(BAR)	SERIAL NO.:
APPLICANT: DeVries et al	TITLE: METHODS AND COMPOSITIONS FOR TREATMENT OF OCULAR NEOVASCULARIZATION AND NEURAL INJURY
FILING DATE: October 30, 2001	GROUP:

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, etc.)

	AO	DiPolo et al, "Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Muller cells temporarily rescues injured retinal ganglion cells", Proc. Natl. Acad. Sci. 95:3978-3983 (1998)
	AP	Chan et al, "Apoptosis in Patients With Posterior Uveitis", Arch Ophthalmol 1997; 115:1559-1567.
	AQ	Buggage et al, ."Apoptosis in cytomegalovirus retinitis associated with AIDS", Curr Eye Res 2000;21:721-729.

EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.